Identifying Target Genes For Novel Anti-epileptic Therapies In The Mouse
Funder
National Health and Medical Research Council
Funding Amount
$469,802.00
Summary
Epilepsy is a disease which affects 2-4% of the population. There are a wide range of drugs available to treat the condition but there is consistently 30-40% of patients who do not respond well to any of these drugs and who continue to have seizures. The reason that there are no drugs available for these people is that most of the drugs available have been designed along the same principles. A new set of principles is needed to develop new drugs which will be able to treat those people not respo ....Epilepsy is a disease which affects 2-4% of the population. There are a wide range of drugs available to treat the condition but there is consistently 30-40% of patients who do not respond well to any of these drugs and who continue to have seizures. The reason that there are no drugs available for these people is that most of the drugs available have been designed along the same principles. A new set of principles is needed to develop new drugs which will be able to treat those people not responding to current therapy. This project is designed to identify new biologic pathways which may be interrupted with drugs to prevent seizures in people with epilepsy. This project uses a procedure to induce mutations into genes in mice and then screens for mice which do not seize when challenged with a drug which generates seizures in mice. Genetic studies will identify the mutated genes and these will be used as potential targets for new therapies or will identify new biological pathway which should expand the use of future anti-epileptic drugs.Read moreRead less
Targeting RCAN1 To Treat Type 2 Diabetes And Obesity
Funder
National Health and Medical Research Council
Funding Amount
$814,468.00
Summary
Obesity and impaired insulin secretion are significant contributors to Type 2 diabetes. In this project we demonstrate that a protein called RCAN1 contributes to both fat mass and insulin secretion and that this contribution is exacerbated in obesity and in Type 2 diabetes. We will identify how RCAN1 controls these major metabolic pathways with outcomes including the development of new therapeutics for obesity and Type 2 diabetes.
Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of ....Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of delivering these by the skin.
This work, in seeking to understand some of the fundamental determinants governing how exogenously applied peptides distribute in the skin, is also contributing to the development of Australian pharmaceutical and cosmetic industries.Read moreRead less
Differentiation of Cord Blood Stem cells into Thymus (T) cells with regulatory phenotype and function. This project will develop technologies for a stem cell therapy platform based on cord blood stem cells, to enable treatment of autoimmune diseases or transplants. Building on the University of Adelaide's frontier demonstration of differentiation of regulatory Thymus (T) cells from cord blood stem cells, the project will develop techniques to expand the numbers of T cells generated. This has the ....Differentiation of Cord Blood Stem cells into Thymus (T) cells with regulatory phenotype and function. This project will develop technologies for a stem cell therapy platform based on cord blood stem cells, to enable treatment of autoimmune diseases or transplants. Building on the University of Adelaide's frontier demonstration of differentiation of regulatory Thymus (T) cells from cord blood stem cells, the project will develop techniques to expand the numbers of T cells generated. This has the potential to maintain Australia's lead in differentiation of cord blood stem cells and to provide a significant breakthrough in potential treatments of autoimmune diseases (e.g. type 1 diabetes) or transplantation. These diseases affect both a healthy start to life and healthy ageing, and an Australian invention to treat or cure them would have global impact.Read moreRead less